Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximabin rheumatoid arthritis;Studio del possibile ruolo predittivo del polimorfismo -174G>C del promotore dell'IL-6 nei confronti della risposta al rituximab in corso di artrite reumatoide

Reumatismo

Volumn 62, Issue 4, 2010, Pages 253-258

  Fabris, M ^a,b   Quartuccio, L ^b   Lombardi, S ^b   Benucci, M ^b   Manfredi, M ^b   Saracco, M ^c   Atzeni, F ^d   Morassi, P ^e   Cimmino, M A ^f   Pontarini, E ^b   Fabro, C ^b   Pellerito, R ^c   Sarzi Puttini, P ^d   Cutolo, M ^f   Carletto, A ^g   Bambara, L M ^g   Fischetti, F ^e   Curcio, F ^a   Tonutti, E ^a   de Vita, S ^b  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b Ospedale San Giovanni di Dio   (Italy)

^c MAURIZIANO HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g UNIVERSITY OF VERONA   (Italy)

Author keywords

IL 6; Pharmacogenetics; Rheumatoid arthritis; Rituximab

Indexed keywords

INTERLEUKIN 6; RITUXIMAB;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PREDICTION; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES;

EID: 79251493474     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by chi-meric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
2. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81.
3. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Fer-raccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pa-thogenetic role of B cells. Arthritis Rheum 2002; 46: 2029-33.
4. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
5. De Vita S, Quartuccio L. Treatment of rheumatoid arthritis with rituximab: an update and possible indications. Autoimmun Rev 2006; 5: 443-8.
6. Dörner T, Burmester GR. New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheu-matol 2008; 20: 263-8.
7. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to ri-tuximab: mechanism of action and identification of bio-markers of response. Ann Rheum Dis 2008; 67: 917-25.
8. Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007; 56: 3909-18.
9. Vos K, Thurlings RM, Wijbrandts CA, van Schaar-denburg D, Gerlag DM, Tak PP. Early effects of ritu-ximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 772-8.
10. Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010; 49: 15-24.
11. Mima T, Nishimoto N. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 2009; 21: 224-30.
12. Fonseca JE, Santos MJ, Canhão H, Choy E. Interleu-kin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009; 8: 538-42.
13. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006;8 (Suppl. 2): S2.
14. Rose-John S, Scheller J, Elson G, Jones SA. Interleu-kin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006; 80: 227-36.
15. Kallen KJ. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Bio-phys Acta 2002; 1592: 323-43.
16. Jones SA, Richards PJ, Scheller J, Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res 2005; 25: 241-53.
17. Panoulas VF, Stavropoulos-Kalinoglou A, Metsios GS, Smith JP, Milionis HJ, Douglas KM, et al. Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis 2009; 204: 178-83.
18. Smith AJP, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Ci-tokyne Growth Factor Rev 2009; 20: 43-59.
19. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yud-kin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-76.
20. Esteve E, Villuendas G, Mallolas J, Vendrell J, López-Bermejo A, Rodríguez M, et al. Polymorphisms in the interleukin-6 receptor gene are associated with body mass index and with characteristics of the metabolic syndrome. Clin Endocrinol (Oxf) 2006; 65: 88-91.
21. Smith AJ, D'Aiuto F, Palmen J, Cooper JA, Samuel J, Thompson S, et al. Association of serum interleukin-6 concentration with a functional IL6 -6331T>C polymorphism. Clin Chem 2008; 54: 841-50.
22. Pascual M, Nieto A, Matarán L, Balsa A, Pascual-Sal-cedo D, Martín J. IL-6 promoter polymorphisms in rheumatoid arthritis. Genes Immun 2000; 1: 338-40.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
24. Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M, et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated withresponse to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 1557-9.
25. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 1998; 20: 247-59.
26. Fabre S, Guisset C, Tatem L, Dossat N, Dupuy AM, Cohen JD, et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. Clin Exp Immunol 2009; 155: 395-402.
27. van Vollenhoven RF, Chatzidionysiou K, Gabay C. Rheumatoid factor predicts response to rituximab in a European registry-based cohort: 6-month results from the collaborative European registries for rituximab in rheumatoid arthritis (CERERRA). Ann Rheum Dis 2009; 68 (Suppl. 3): 579.
28. Reich D, Patterson N, Ramesh V, De Jager PL, McDonald GJ, Tandon A, et al. Admixture mapping of an alle-le affecting interleukin 6 soluble receptor and interleukin 6 levels.; Health, Aging and Body Composition (Health ABC) Study. Am J Hum Genet 2007; 80: 716-26.
29. Buch MH. Sequential use of biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2010; 22: 321-9.